Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer. | Int J Mol Sci | 2023 | 38068911 | PubTator, text mining | PubMed |
| Emerging Microfluidic Tools for Simultaneous Exosomes and Cargo Biosensing in Liquid Biopsy: New Integrated Miniaturized FFF-Assisted Approach for Colon Cancer Diagnosis. | Sensors (Basel) | 2023 | 38067805 | PubTator, text mining | PubMed |
| Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer. | Cancers (Basel) | 2023 | 38067208 | PubTator, text mining | PubMed |
| Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma. | Medicine (Baltimore) | 2023 | 38050240 | PubTator, text mining | PubMed |
| Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity. | Front Immunol | 2023 | 38045695 | PubTator, text mining | PubMed |
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study). | Front Immunol | 2023 | 38022553 | PubTator, text mining | PubMed |
| TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients. | BMC Cancer | 2023 | 38017389 | PubTator, text mining | PubMed |
| Exploiting innate immunity for cancer immunotherapy. | Mol Cancer | 2023 | 38008741 | PubTator, text mining | PubMed |
| Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy. | Cancers (Basel) | 2023 | 38001645 | PubTator, text mining | PubMed |
| Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives. | Curr Issues Mol Biol | 2023 | 37998754 | PubTator, text mining | PubMed |
| Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma. | Sci Rep | 2023 | 37993470 | PubTator, text mining | PubMed |
| [Research Progress of Lung Cancer Vaccines]. | Zhongguo Fei Ai Za Zhi | 2023 | 37985155 | PubTator, text mining | PubMed |
| Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines. | J Transl Med | 2023 | 37978542 | PubTator, text mining | PubMed |
| Building safety into CAR-T therapy. | Hum Vaccin Immunother | 2023 | 37968136 | PubTator, text mining | PubMed |
| The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank. | Front Immunol | 2023 | 37965317 | PubTator, text mining | PubMed |
| Cytotoxic CD4+ T cells in chronic viral infections and cancer. | Front Immunol | 2023 | 37965314 | PubTator, text mining | PubMed |
| GPC3 Promotes Lung Squamous Cell Carcinoma Progression and HLA-A2-Restricted GPC3 Antigenic Peptide-Modified Dendritic Cell-Induced Cytotoxic T Lymphocytes to Kill Lung Squamous Cell Carcinoma Cells. | J Immunol Res | 2023 | 37965271 | PubTator, text mining | PubMed |
| High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma. | BMC Cancer | 2023 | 37957631 | PubTator, text mining | PubMed |
| Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy. | Cancer Cell Int | 2023 | 37951911 | PubTator, text mining | PubMed |
| Tumor-derived systems as novel biomedical tools-turning the enemy into an ally. | Biomater Res | 2023 | 37946275 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers?page=7